| Year |
Citation |
Score |
| 2018 |
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, et al. Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29549161 DOI: 10.1158/1078-0432.Ccr-17-2262 |
0.311 |
|
| 2017 |
Mathews S, Finn G, Kudla AJ, Rimkunas V, Laivins P, MacBeath G, Czibere A, Baum J. Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A19 |
0.307 |
|
| 2017 |
Finn G, Zhang H, Blois A, Mathews s, Kudla A, Baum J, Cieslewicz M, macbeath g, Adiwijaya B, Czibere A. Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A14 |
0.312 |
|
| 2015 |
Pace E, Adams S, Camblin A, Curley M, Rimkunas V, Nie L, Iadevaia S, Tan G, Baum J, Czibere AG, Lugovskoy A. Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology. 33: 289-289. DOI: 10.1200/Jco.2015.33.3_Suppl.289 |
0.359 |
|
| 2014 |
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ, Schoeberl B, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics. 13: 410-25. PMID 24282274 DOI: 10.1158/1535-7163.Mct-13-0255 |
0.327 |
|
| 2013 |
Adams S, Baum J, Sparta B, Rimkunas V, Tang J, Pace E, Rosenthal S, Camblin A, Iadevaia S, Czibere A, Nielsen U, Lugovskoy A. Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C169 |
0.339 |
|
| 2012 |
Johnson B, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A, Adams S, Baum J, Tang J, Iadevaia S, Kohli N, Rennard R, Sundararajan P, Xu L. Abstract A38: MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A38 |
0.353 |
|
| 2011 |
Lugovskoy A, Johnson B, Baum J, Adams S, Tang J, Kohli N, Rennard R, Xu L, Jiao Y, Nilesen U, Fitzgerald J. Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B205 |
0.346 |
|
| 2007 |
Baum JS, Arama E, Steller H, McCall K. The Drosophila caspases Strica and Dronc function redundantly in programmed cell death during oogenesis. Cell Death and Differentiation. 14: 1508-17. PMID 17464325 DOI: 10.1038/Sj.Cdd.4402155 |
0.607 |
|
| 2005 |
Baum JS, St George JP, McCall K. Programmed cell death in the germline. Seminars in Cell & Developmental Biology. 16: 245-59. PMID 15797835 DOI: 10.1016/J.Semcdb.2004.12.008 |
0.581 |
|
| 2004 |
McCall K, Baum JS, Cullen K, Peterson JS. Visualizing apoptosis. Methods in Molecular Biology (Clifton, N.J.). 247: 431-42. PMID 14707364 |
0.553 |
|
| 2003 |
Laundrie B, Peterson JS, Baum JS, Chang JC, Fileppo D, Thompson SR, McCall K. Germline cell death is inhibited by P-element insertions disrupting the dcp-1/pita nested gene pair in Drosophila. Genetics. 165: 1881-8. PMID 14704173 |
0.589 |
|
| Show low-probability matches. |